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Purpose: To evaluate use of breath-hold CTs and implanted fiducials for definition of the internal target volume
(ITV) margin for upper abdominal stereotactic body radiation therapy (SBRT). To study the statistics of inter- and
intra-fractional motion information.
Methods and materials: 11 patients treated with SBRT for locally advanced pancreatic cancer (LAPC) or liver
cancer were included in the study. Patients underwent fiducial implantation, free-breathing CT and breath-hold CTs
at end inhalation/exhalation. All patients were planned and treated with SBRT using volumetric modulated arc therapy
(VMAT). Two margin strategies were studied: Strategy I uses PTV = ITV + 3 mm; Strategy II uses PTV = GTV + 1.5 cm. Both
CBCT and kV orthogonal images were taken and analyzed for setup before patient treatments. Tumor motion statistics
based on skeletal registration and on fiducial registration were analyzed by fitting to Gaussian functions.
Results: All 11 patients met SBRT planning dose constraints using strategy I. Average ITV margins for the 11 patients
were 2 mm RL, 6 mm AP, and 6 mm SI. Skeletal registration resulted in high probability (RL = 69%, AP = 4.6%, SI = 39%)
that part of the tumor will be outside the ITV. With the 3 mm ITV expansion (Strategy 1), the probability reduced to RL
32%, AP 0.3%, SI 20% for skeletal registration; and RL 1.2%, AP 0%, SI 7% for fiducial registration. All 7 pancreatic
patients and 2 liver patients failed to meet SBRT dose constraints using strategy II. The liver dose was increased by 36%
for the other 2 liver patients that met the SBRT dose constraints with strategy II.
Conclusions: Image guidance matching to skeletal anatomy is inadequate for SBRT positioning in the upper abdomen
and usage of fiducials is highly recommended. Even with fiducial implantation and definition of an ITV, a minimal
3 mm planning margin around the ITV is needed to accommodate intra-fractional uncertainties.
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Image guided radiotherapy (IGRT) has improved the ac-
curacy of radiation therapy (RT) by providing 3D imaging
registration based on volumetric anatomic information. A
linear accelerator (LINAC) treatment machine equipped
with cone beam computed tomography (CBCT) can
acquire high resolution images with excellent skeletal
anatomy contrast and useful soft tissue contrast. This
allows for significantly improved registration and tumor* Correspondence: Wensha.Yang@cshs.org
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reproduction in any medium, provided the ortargeting accuracy as compared to skeletal anatomy-based
registration using either kV or MV portal images. Lung
treatments have benefited greatly from the use of CBCT
due to low density. On the other hand, many tumor
targets do not show sufficient soft tissue contrast using
CBCT [1], thereby rendering it ineffective other than
for skeletal anatomy registration. However, use of skeletal
anatomy only can result in significant geometrical errors.
This lack of tumor and soft tissue CT contrast is a prom-
inent problem in the abdominal and pelvic regions, where
organs are substantially influenced by both inter- and
intra-fractional motion [2,3]. In most conventionally frac-
tionated RT, generous margins have been used to accountd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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position in this anatomical region.
Increasingly, stereotactic body radiation therapy (SBRT)
is being utilized to treat hepatic and pancreatic cancers
given the improved local control rates compared to
conventionally fractionated RT [4,5]. During SBRT, higher
doses per fraction are delivered, thereby increasing the
risk of injury to nearby uninvolved critical organs, which
then motivates attempts at more aggressive margin re-
duction strategies. Recognizing the deficiencies in tissue
contrast using CBCT for upper abdominal SBRT guidance,
a number of clinical investigators have started to implant
fiducial markers in abdominal organs, mainly under
endoscopic ultrasound (EUS) guidance [6-9]. In addition
to allowing more accurate daily tumor targeting, fiducial
markers also provide an excellent opportunity to examine
inter- and intra-fractional motion of the tumor relative to
the skeletal anatomy, with the ultimate aim of minimizing
target volume margins in a patient-specific manner.
However, published data on this topic are still limited.
Varadarajulu et al. reported on inter-fractional discrepan-
cies between skeletal landmark and intra-pancreatic fiducial
alignment using kV 2D images [10], however, this snapshot
of fiducial position could not differentiate inter-fractional
motion from intra-fractional motion. The relative uncer-
tainty associated with predicting inter- and intra-fractional
motion during free-breathing SBRT of abdominal tumors
can have a significant impact on planning dosimetry and
potentially even clinical outcomes.
To overcome this problem, in this work we assess the
utility of breath-hold simulation CT scans for motion
assessment and free-breathing treatment of pancreatic
and liver cancer patients implanted with fiducial markers
and guided using CBCT and kV 2D imaging, which
samples the probability density motion distribution of
the fiducials while patient is breathing. Specifically, we
attempt to 1) evaluate commonly used planning target
volume (PTV) margin calculation methods for skeletal
anatomy and fiducial marker alignment, respectively.
The first method is a tight margin on ITV, and the second
is a generous margin on GTV; 2) determine whether the
internal target volume (ITV) margin can be accurately
predicted from the pre-treatment tumor motion range
evaluated using inhale and exhale breath-hold CT simu-
lation scans; and 3) the variation in intra- and inter-
fractional tumor motion as inferred from the location of
implanted fiducial markers.
Methods and materials
Fiducial placement, CT-simulation and motion assessment
Eleven consecutive patients with locally advanced pancre-
atic (n = 7) or liver (n = 4) cancer were studied under an
IRB approved protocol. Prior to CT simulation, patients
were implanted with 2–5 radio-opaque fiducial markers(Visicoil, IBA; 0.75 × 3 mm) in the periphery of the tumor,
with 2–3 fiducials around each lesion under EUS guidance
[11]. More than 72 hours after implantation, patients
underwent CT simulation and were positioned on a wing
board with both arms raised above the head using Vac-Lok™
(MED-TEC, Orange City, IA) bag immobilization.
Patients were scanned from the carina to L5/S1 using
a dual slice GE high speed NXi scanner with 2.5 mm slice
thickness while free breathing (FB) after receiving oral and
intravenous (IV) contrast. They were then instructed to
inhale normally and hold their breath while an inhale
breath-hold (IBH) scan was performed. Similarly, an exhale
breath-hold (EBH) CT was performed. The tumor was first
identified on the FB scan and IBH/EBH scans were then
taken with images obtained 25 slices superior and inferior
to the tumor. The motion range of individual fiducial
markers was calculated using the coordinates of the fiducial
on the IBH and EBH scans. The average displacements of
the fiducials in RL (right- left) δx, AP (anterior-posterior)
δy and SI (superior-inferior) δz directions, respectively,
were used to create the non-isotropic GTV to ITV margin
using the margin tool provided in Eclipse. Figure 1a shows
the margin expansion strategy.
Treatment planning
The GTV was drawn to include the gross primary tumor
and enlarged lymph nodes considered suggestive of meta-
static involvement on diagnostic imaging (CT and/or PET).
The GTV was identified on FB simulation CT scan, which
was obtained with both intravenous and oral contrast [12].
Two margin strategies were investigated. In strategy I, the
PTV was defined as the ITV with a 3 mm isotropic expan-
sion [13]. This was the clinically implemented strategy
based on the availability of fiducial markers for the SBRT
daily alignment. All patients were treated with 25–40 Gy
in 5 daily fractions. Volumetric modulated arc therapy
(VMAT) with 2–3 arcs was used for treatment planning
for all patients in the study [14]. Treatment plans were
optimized so at least 90 - 100% of the PTV received the
prescription dose, with maximum allowable dose of 120%.
All plans were optimized to meet the clinically used normal
tissue dose constraints including: Dmax < 8 Gy for cord,
D75% < 12Gy for combined kidneys, mean dose < 12Gy for
liver-GTV, and V15Gy < 9 cc, V20Gy < 3 cc, D50% < 12Gy,
Dmax < 33Gy for stomach, duodenum, and small bowel
[15]. In strategy II, a 1.5 cm GTV to PTV expansion was
used without ITV calculation. Identical prescriptions and
normal tissue dose constraints were used. The number of
patients who did not meet the SBRT dose constraints was
identified.
Treatment delivery
Prior to each treatment fraction, both CBCT and one











































Figure 1 GTV to ITV margin expansion and respiratory fiducial motion for all patients. a. GTV(red) to ITV(black( expansion strategy. b. The
motion range evaluated from breath-hold CTs for 11 patients (1–7 are pancreas patients, 8–11 are liver patients), with averages 0.6 (0–1.8) cm AP,
0.6 (0.1-1.5) cm SI, and 0.2 (0.1-0.7) cm RL.
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the position of the tumor. CBCT was first aligned to
the FB planning CT using the skeletal anatomy. A second
registration was then performed with alignment to fiducials
(with a 2 mm tolerance). The relative couch shifts between
the skeletal and fiducial registrations after CBCT were
used to evaluate the differences in soft tissue displacement
(“bone-marker difference”). kV images were then obtained
and registered to fiducials after CBCT fiducial shifts.
The resulting displacement from CBCT-matching to
kV-matching was recorded as CBCT-kV difference.
Results
All patients tolerated the EUS-guided fiducial placement
without any associated morbidity. A total of 33 fiducials
were implanted. We noted no migration or loss of markers
from time of placement until the end of treatment. As
shown in Figure 1b, calculation of the respiratory motion
range of fiducial markers from the BH CT images showed
the average motion in the RL direction was significantly less
than the two other directions. Four patients showed greater
than 1 cm motion in one or more directions; two had
pancreatic tumors, while 2 had liver tumors. The average
ITV margins for the 11 patients were 2 mm RL, 6 mm AP,
and 6 mm SI.
When CBCT was registered to the simulation CT using
skeletal anatomy, a visible discrepancy in the location
of fiducial markers was noted between the two scans
(Figure 2a-c). To evaluate whether the extent of the
bone-marker differences was related to the respiratory
motion range, the standard deviations of the bone-markerdifferences for each patient were plotted against the fiducial
displacements calculated from the simulation BH CTs for
AP, SI, and RL directions. No significant (>0.8) correlation
was observed. The distribution of the bone-marker regis-
tration differences for all patients was subsequently
analyzed (Figure 3a-c). Unlike the respiratory motions
measured from the BH CTs, on average, the smallest
absolute bone-marker difference was observed in the
AP direction (2 mm), followed by 3 mm in both RL and
SI directions. The differences were symmetric about the
skeletal registration, showing no systematic bias or
drift in any particular direction. Each histogram was fit
to a Gaussian function. As shown in Table 1, if skeletal
landmarks alone were used for image guidance, the prob-
abilities of not covering a portion of the tumor during the
treatment using different margin strategies were listed. The
frequencies of the bone-marker differences in <0.3 cm,
0.3 - 0.5 cm, 0.5 - 1 cm, 1 - 1.5 cm, >1.5 cm range were
plotted in Figure 3d-f in three motion axes, with the
majority (>90%) of the fractions having the bone-marker
difference less than 1 cm.
Each CBCT acquisition takes about 1 minute, during
which time multiple respiratory breathing cycles have
occurred. The resultant CBCT image thus is representa-
tive of the tumor average position. On the other hand, kV
2D images take less than 1 second to acquire and are
snapshots which can occur at any phase of the breathing
cycle. As all patients were otherwise well immobilized, the
differences in fiducial positions between CBCT and kV
imaging are most likely attributable to the patients’
breathing. The kV 2D images were obtained after applying
a. 
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Figure 2 Example images of fiducial motion and DRR to kV registration; flow chart of pre-treatment image registration. a. A typical
pre-RT CBCT registered to planning CT using skeletal landmarks. b. Fiducial displacement from planning CT to CBCT with skeletal alignment for a
pancreas patient. c. Fiducial displacement from planning CT to CBCT with skeletal alignment for a liver patient. d-e. an example of kV orthogonal
images with fiducial matching to the contour derived from DRR. f. Flow chart describes how the imaging guidance was performed before the
treatment and how the shifts were resolved.
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To understand the intra-fraction motion of the fiducials
during daily treatment, the difference in positional location
of fiducials between CBCT and kV 2D images obtained
prior to each treatment fraction was determined. An ex-
ample of kV orthogonal images matching to the fiducial
contours derived from DRR was shown in Figure 2d-e.
The standard deviation of CBCT-kV 2D difference for
each patient was plotted against the breathing motion
range evaluated from the BH CTs. A weak correlation
was noted in the AP and RL directions, but not in the
SI direction. The positional differences between fiducialsidentified on kV 2D images and CBCT images are shown
in histograms of the three motion axes (Figure 4a-c). Note
that the intrafractional motion was mainly due to the
respiratory motion that was included in the ITV margin,
which is in addition to the 3 mm ITV to PTV margin.
Each distribution is generally Gaussian and the deviations
are symmetric about the average marker position in the
CBCT. The average standard deviations of kV 2D-CBCT
marker distances are 1 mm AP, 1 mm RL and 2 mm SI.
Using the reasonable assumption that the CBCT-kV 2D
marker distances are a random sampling of the respiratory
motion for the patient cohort combined with Gaussian
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Figure 3 Statistics for bone to fiducial shifts. a-c. Histograms of bone-marker discrepancies for AP, SI, and RL directions, respectively. Gaussian
fits of the histograms give average (μ) and standard deviation (σ) values in each of the three directions. d-f. Bar plots of % of fractions that has
bone-marker shifts in <0.3 cm, 0.3 - 0.5 cm, 0.5 - 1 cm, 1 - 1.5 cm, and >1.5 cm for AP, SI and RL directions.
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motion on the probability of not covering the entire GTV
using different margin strategies were listed in Table 2.
The frequencies of CBCT to kV shifts in <0.3 cm, 0.3 -
0.5 cm, 0.5 - 1 cm, 1 - 1.5 cm, >1.5 cm range were plotted
in Figure 4d-f in three motion axes, with the majority
(>98%) of the fractions having the bone-marker difference
less than 1 cm
All plans evaluated using strategy I met the SBRT
planning criteria. All 7 pancreatic and 2 liver patients
did not meet one or more of the normal tissue dose con-
straints using strategy II due to the close proximity of
one or more critical organs to the PTV. The liver dose
was increased by 36% for the other 2 liver patients that
met the SBRT dose constraints with strategy II. Figure 5
shows the dosimetric results for organs at risk, with 90 ~
100% of PTV receiving the prescription dose. Strategy II
significantly (p < 0.05) increased doses for stomach, duo-
denum, bowel and cord, comparing to strategy I. Strategy
II also increased doses to total kidneys and liver, although
statistically non-significantly with p value of 0.1 and 0.2,
respectively.Table 1 Probability of not covering the entire GTV (%)
Method RL AP SI Total
Registration using skeletal landmarks alone 69% 4.6% 39% 82%
Strategy I (PTV = ITV + 3 mm) 32% 0.3% 20% 46%
Strategy II (PTV = GTV + 1.5 cm) 0.3% 0% 3.6% 4%Discussion
4DCT has been widely used for the evaluation of respira-
tory motion for lung cancer to assess ITV. However,
relevance and applicability of 4DCT to abdominal tumors
has not been investigated as thoroughly. A recent study
from Ge et al. reported that planning 4DCT cannot ad-
equately represent daily intra-fractional motion of abdom-
inal tumors [16]. Study also showed that the maximum
intensity projection (MIP) is not useful in determining
pancreatic ITV and manual contours are needed [17].
When compared against real-time dynamic MRI images,
the deficiency of 4DCT in evaluating motion in abdominal
regions is clear [18-20]. For centers without 4DCT,
breath-hold CT is one of the limited options left to evalu-
ate tumor motion. It is a valid method to assess abdominal
tumor motion [21], and recognized by AAPM task group
76. The use of breath-hold CTs in combination with IV
and oral contrast can help clinicians in accurate target
definition in both inhale and exhale breath-hold phases.
In this study, we have used breath-hold CT to create the
ITV, which has the advantages of higher imaging quality
and being free from motion artifacts. The accuracy of ITV
may be affected by the GTV derived from free-breathing
CT which can be motion-blurred, but we expect the effect
to be small due to fast 16-row CT acquisition.
Utilization of both CBCT and kV 2D imaging allows
pretreatment identification of fiducial markers in both
the average and instantaneous positions, respectively. A
previous study using kV 2D imaging alone for pretreatment
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Figure 4 Statistics for CBCT to kV shifts. a-c. Histograms of differences between CBCT and kV 2D images for AP, SI, and RL directions,
respectively. Gaussian fits of the histograms determine the average (μ) and standard deviation (σ) for each of the three directions. d-f. Bar plots of
% of fractions that has CBCT to kV shifts in <0.3 cm, 0.3 - 0.5 cm, 0.5 - 1 cm, 1 - 1.5 cm, and >1.5 cm for AP, SI and RL directions.
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reported a motion distribution of 0.2 cm (0.1–0.5 cm),
0.5 cm (0.2–1.5 cm), and 0.4 cm (0.2–0.9 cm) in AP, SI
and RL axes, respectively [10]. This distribution is consist-
ent with motion calculated from the fiducial displacement
on BH CTs in this study. However, the availability of BH
CTs, IGRT with CBCT, and kV 2D imaging lends another
dimension to the current analysis. Multiple breathing
cycles occur during each CBCT acquisition, so the CBCT
images of the markers represent an average position of the
markers. The magnitudes of the differences between
the bone and marker registrations are a measure of the
inter-fractional mobility in the region.
Without using implanted fiducial markers, Shiinoki et al.
[22] studied inter- and intra- fractional tumor motion of
15 pancreatic cancer patients using sequential 4DCT
during the treatment course. They observed intra- and
inter-fractional motion similar to the results obtained
here. Mori et al. [23] used high speed 256-row CT to
study the intra-fractional pancreatic tumor motion of 6
patients and reported significantly smaller motion in
the AP direction than the current work. It is worth noting
that these previous studies were unavoidably limited by
the intrinsic uncertainties associated with identification
and tracking of an organ with low soft tissue CT contrast;
the current study provides strong rationale for the use ofTable 2 Influence of Intra-treatment motion on the
probability of not covering the entire GTV (%)
Method RL AP SI Total
PTV = ITV 32% 0.3% 23% 48%
PTV = ITV + 3 mm 1.2% 0% 7% 8%fiducial markers as a defined surrogate facilitating more
accurate tumor and motion assessment.
The significance of this study should be evaluated in the
context of SBRT, where the potential for improvements in
local control needs to be balanced against possible normal
tissue toxicity. Standard chemo-radiotherapy treatment of
non-metastatic, unresectable pancreatic adenocarcinoma
results in a median survival of 11–12 months, with a high
probability of local persistence of disease and poor local
control [24]. Whereas use of intensity modulated radiation
therapy (IMRT) has reduced normal tissue dose, resulting
in improved toxicity rates, it has not allowed clinically
meaningful dose escalation using standard fractionation
[25]. Local control rates of pancreatic and liver tumors
have been dramatically improved following SBRT, although
normal tissue toxicities remain high and an impediment to
further dose-escalation [26,27]. Concern about the normal
tissue toxicity can be partially addressed by improving the
geometrical targeting accuracy and confidently reducing
treatment margins. In this study, use of skeletal anatomy
alignment is shown to result in inaccurate tumor targeting,
due to both inter- and intra-fractional tumor motion, and
that inaccuracy could not necessarily be accounted for
using an ITV. Treatment based on skeletal registration
necessitated use of a larger GTV to PTV expansion if
the GTV was to be adequately covered. A 1.5 cm isotropic
GTV to PTV margin minimally met the coverage require-
ment, but also resulted in higher normal tissue doses; in
most cases, planning constraints were not met and pa-
tients would not have qualified for the SBRT. Similarly, a
3 mm ITV to PTV margin, which is typical for SBRT
treatment, resulted in grossly inadequate PTV coverage
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Figure 5 Box plots of normal tissue doses for two strategies. All cases satisfied 90 - 95% of PTV receiving the prescription dose. a. V15 and
V20 for stomach, duodenum and bowel; b. maximum dose for cord, D75% for total kidneys and mean dose for liver. *statistically significant with
p < 0.05
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the non-isotropic ITV margin expansion may also not be
appropriate in this setting, as it does not adequately
account for intra- and inter-fraction motion. These results
highlight the inadequacy of skeletal registration and
further stress the necessity of appropriate soft tissue
registration using implanted fiducial markers for SBRT.
The comparison of the pretreatment snapshot 2D kV
images to CBCT provided interesting insight into intra-
fractional motion. The kV-based shifts weakly correlated
with and in some instances also exceeded the magnitude
of the ITV margin defined using the BH CTs, suggesting
that a portion of the tumor could potentially be outside
the ITV for a non-negligible percentage of the time;
however, this probability decreased significantly with
the addition of a 3 mm PTV margin. One pair of kV
images is inadequate to provide a complete motion tra-
jectory. However, we agree that the probability density
distribution function of the tumor moving trajectory is
Gaussian and kV imaging sampling is random, then the
power to determine the mean and deviation of a Gaussian
function with 100 samples is approximately 0.85, which is
not perfect but useful. Although the significance of this
finding is not clear, it implies that intra-fraction motion
may not be appropriately accounted for using an ITV
calculated from BH CTs. Additionally; our data suggeststhat without breathing motion management, such as gated
or breath-hold treatments, current ITV and PTV margins
cannot be further reduced. Certainly, such planning limi-
tations may in turn constrain the ability to dose escalate
treatment. To better characterize the pattern of intra-
fractional motion, the marker position needs to be continu-
ously monitored through analysis of CBCT projections [28]
or by using radiofrequency transponders.
It has been reported that greater tumor respiratory
motion amplitudes are correlated to the baseline drift [29]
that affects interfractional tumor position reproducibility.
The correlation would have considerable implication on
the calculation of ITV and PTV margins, e.g. larger ITV
margins also warrant larger PTV margins in cases without
implanted fiducials. In this study, we investigated the
correlation between pretreatment tumor breathing motion
amplitude and the magnitude of bone-fiducial registration
discrepancy but did not find the correlation.
Whereas the use of implanted fiducial markers and the
number of studies investigating their application in the
treatment of abdominal tumors is increasing significantly,
there are several potential issues related to their use which
warrant further study. For example, the distance and
spatial relationship between multiple implanted markers
and the tumor can potentially change due to treatment
and/or disease-related organ swelling or shrinkage. In
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the tumor may change throughout the breathing cycle due
to possible differential motion caused by organ deformation
[30]. Finally, although less likely [31], the issue of fidu-
cial migration and/or loss during treatment may occur.
Whereas these variables are beyond the scope of this
study, they are worth noting when considering an upper-
abdominal SBRT program involving EUS-guided placement
of fiducial markers.Conclusions
Breath hold CT, CBCT and 2D kV images were used to
track upper-abdominal tumor motion in 11 patients with
intra-tumoral fiducials planned to receive SBRT. Similar
to other studies, no morbidity or migration was associated
with endoscopic fiducial placement. Tumor motion was
greatest in the SI direction. Significant differences in
alignment were noted between the skeletal anatomy
and the fiducial registration. Interestingly, these differences
did not correlate with tumor motion amplitudes as quanti-
fied by BH CTs. Following skeletal alignment, a 3 mm PTV
margin from the ITV proved insufficient for tumor cover-
age, while a 1.5 cm margin around the GTV exceeded
normal tissue planning constraints. Taken together, these
data suggest inadequacy of skeletal alignment and under-
score the importance of intra-tumoral fiducials for daily
alignment prior to SBRT. Intra-fraction tumor motion, as
assessed by snapshot kV 2D imaging, showed only modest
correlation with ITV margin calculation, and there was a
significant probability that portions of the tumor may not
be adequately covered if a 3 mm PTV expansion were not
added. These data suggest that further attempts at margin
reduction for SBRT treatment of intra-abdominal tumors
should incorporate motion adaptive radiotherapy with
explicit fiducial tracking or breath-hold techniques.Competing interests
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